By Zeke Miller and Darlene Superville 

Updated 6:10 pm ET

President Donald Trump said Monday that he is taking a malaria drug to protect against the new coronavirus, despite warnings from his own government that it should only be administered for COVID-19 in a hospital or research setting due to potentially fatal side effects.

Trump told reporters he has been taking the drug, hydroxychloroquine, and a zinc supplement daily “for about a week and a half now.” Trump spent weeks pushing the drug as a potential cure or prophylaxis for COVID-19 against the cautionary advice of many of his administration's top medical professionals. The drug has the potential to cause significant side effects in some patients and has not been shown to combat the new coronavirus.

Trump said his doctor did not recommend the drug to him, but he requested it from the White House physician.

"I started taking it, because I think it’s good," Trump said. "I’ve heard a lot of good stories.”

The Food and Drug Administration warned health professionals last month that the drug should not be used to treat COVID-19 outside of hospital or research settings, due to sometimes fatal side effects. Regulators issued the alert for the drug, which can also be used to treat lupus and arthritis, after receiving reports of heart-rhythm problems, including deaths, from poison control centers and other health providers.

Trump dismissed reports of side effects, saying, “All I can tell you is, so far I seem to be OK.”

At least two White House staffers tested positive for COVID-19 earlier this month, sparking concerns about the steps taken by the administration to protect the president and sending Vice President Mike Pence and other officials into varying forms of self-isolation.

The White House has since mandated that those in the West Wing wear face coverings and has introduced daily testing for the virus for the president, vice president, and those they come in close contact with.

Trump last underwent an “interim” checkup in a November visit to Walter Reed National Military Medical Center that was not noted on his public schedule. His last complete physical took place in February 2019.

Trump has repeatedly pushed the use of the drug with or without the antibiotic azithromycin, but no large, rigorous studies have found them safe or effective for preventing or treating COVID-19.

Two large observational studies, each involving around 1,400 patients in New York, recently found no benefit from hydroxychloroquine. Two new ones published Thursday in the medical journal BMJ reached the same conclusion.

One, by French researchers, gave 84 hospitalized patients the drug and 97 others the usual care. There were no differences in the odds of death, need for intensive care or developing severe illness.

The other study from China was a stricter test: 150 adults hospitalized with mild or moderate illness were randomly assigned to get hydroxychloroquine or usual care. The drug made no difference in rates of clearing the virus or time to relief of symptoms, and they brought more side effects.

In April, the National Institutes of Health launched a study testing hydroxychloroquine versus a placebo drug in 500 hospitalized COVID-19 patients. Last week, NIH announced another study to see if hydroxychloroquine plus azithromycin can prevent hospitalization or death in people with mild to moderate illness. About 2,000 U.S. adults with confirmed coronavirus infections and symptoms such as fever, cough, or shortness of breath will get the drugs or placebo pills.

U.S. prescriptions for hydroxychloroquine surged roughly 80% in March to more than 830,000 compared with the same period in the prior year, according to data tracking firm IQVIA. That jump in prescribing came before the federal government accepted nearly 30 million doses of the drug donated to the strategic national stockpile by foreign drugmakers. Since then, millions of those tablets have been shipped to U.S. hospitals nationwide for use treating patients with COVID-19.

—-

AP medical writers Marilynn Marchione in Milwaukee and Matthew Perrone in Washington contributed to this report.

Share:
More In Politics
Jan. 6 Committee Asks Ivanka Trump to Give Voluntary Testimony
The January 6 committee has asked Ivanka Trump to give voluntary testimony, saying there's evidence she was in "direct contact" with her father on the day of the capitol insurrection. I's unclear whether she will comply with the invitation, but it marks the first time the House committee has sought testimony from a member of the former president's family. Bradley Moss, national security attorney, joined Cheddar News to discuss what the committee hopes to learn from Ivanka and what the Supreme Court's decision on Trump's Jan. 6 materials means for the investigation.
States Turn to Unusual Solutions as Schools Face Staffing Shortages
With an increasing number of teachers and staff calling out sick by the day, the state of Oklahoma is turning to an unusual solution. Republican Governor Kevin Stitt has issued an executive order that permits state employees to work as substitute teachers. Shaily Baranwal, founder and CEO of Elevate K-12, joins Cheddar News to discuss.
Possible Cracks Between U.S. and Allies on Issue of Ukraine and Russia
On Thursday, Secretary of State Antony Blinken addressed the stance of the U.S. and its allies should Russia make any forays into Ukraine, a seeming response to President Biden's remarks that should Putin engage in something short of a full invasion, there might be some indecision among allied nations regarding what to do. Ariel Cohen, a senior fellow at the think tank Atlantic Council, joined Cheddar to discuss the difficulty faced by Blinken wrangling unity as tensions run high in the region. "There'll be a smaller incursion, and the president implied, there'll be a weaker response because our European allies have created this horrible situation where they are dependent on Moscow for their gas supply," Cohen explained.
Biden Approval Rating Tanking at One-Year Mark Over Issues Like Inflation
During a nearly two-hour press conference on Wednesday, President Biden spoke on his accomplishments and challenges from the first year of his presidency, and what his administration hopes to accomplish in the coming year. However, his approval ratings are underwater as COVID remains a big concern for voters — as does inflation, noted Tom Bevan, co-founder and president of polling aggregator RealClearPolitics. "The public thinks [inflation] is priority number one, and the administration is concerned about it, they talk about it, but they're not spending enough time on it as far as the public is concerned," said Bevan.
Behind Australian Judges Ruling for Allowing Novak Djokovic Deportation
The drama surrounding tennis star Novak Djokovic continues after he was deported from Australia over the weekend due to the nation's COVID-19 vaccine requirements. Djokovic was forced to leave the country on the eve of what was to be his first match in defense of his Australian Open title after three judges ruled in favor of his removal and revealed their reasoning for doing so. Adding to his woes, a law recently passed in France is putting his chances of defending his French Open title in jeopardy. The director of Marist's Center for Sports Communication, Jane McManus, joined Cheddar to discuss the ongoing fallout.
Louisiana Senate Candidate on Smoking Weed in His Campaign Ad
As the midterm elections get ever closer, candidates have been getting creative with their campaigns to stick out and to connect with voters. Gary Chambers, a Democratic candidate for the U.S. Senate from Louisiana, has definitely attracted attention with an advertisement featuring him smoking a blunt, making a point about the inequity of anti-cannabis laws. "We wanted to bring the seriousness of the moment," he said of the ad. "But we also wanted to make sure that people understand that there are 19 states that are legal right now but Black people and brown people are being over-incarcerated in mostly Southern and Midwestern states in America for cannabis possession."
Load More